Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Specialty Natural Products Public Company Limited (SNPS.BK)
Chonburi, BKK, TH
Specialty Natural Products Public Company Limited manufactures and distributes herbal extracts, cosmetics, beverages, health supplements, and traditional medicines in Thailand and internationally. The company also offers extracts for nutraceuticals and cosmeceuticals for use in weight and immune control, blood pressure and sugar, antiaging, hair nourishment, whitening, wound healing, UV protection, rejuvenation for men, slimming, cosmetic mosturerizing, antibacterial, antioxidant, nutrition, and anti-inflammatory; natural additives, such as eucalyptus, ginger, jojoba, kaffir lime, lavender, lemon, lemongrass, lime, orange, peppermint, plai, turmeric, rice bran, and tea tree oil; and other additives, including amino cleansers, concentrate shampoo, SNP-alpha arbutin, Argirena, clear soap, cremaflow, emulbase, ICM, nonawax, polyol complex, solubilisant, standard EB, surfactant base1, sunsil tin50, tiospere 50BG, TOG, supersil E, and standard EB. In addition, it provides herbal active pharmaceuticals ingredients comprising senna extract liquid and andrographis extract powder; packing services for cosmetics, beverages, and dietary supplements; production and distribution of electricity; and product research and development services. The company was incorporated in 1999 and is headquartered in Chonburi, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.45% | -4.27% | -8.57% | -4.68% | -6.28% | -0.44% | -11.29% | +6.16% | +6.16% | +6.16% | +6.16% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+21.2% ★ Q1'26: +1.7% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+40.0% ★ Q1'26: +34.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+8.4% Q1'26: +17.4% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+21.8% ★ Q1'26: +25.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+22.2% ★ Q1'26: +22.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.02× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
457.31M
est: 467.00M (-2.1%)
|
554.21M
est: 560.00M (-1.0%)
|
652.00M
652.00M – 652.00M
+16.4% YoY
|
737.00M
737.00M – 737.00M
+13.0% YoY
|
791.00M
791.00M – 791.00M
+7.3% YoY
|
| EBITDA |
122.09M
est: 121.44M (+0.5%)
|
147.16M
est: 145.63M (+1.1%)
|
169.55M
169.55M – 169.55M
+16.4% YoY
|
191.65M
191.65M – 191.65M
+13.0% YoY
|
205.70M
205.70M – 205.70M
+7.3% YoY
|
| EBIT |
94.81M
est: 96.30M (-1.5%)
|
120.75M
est: 115.47M (+4.6%)
|
134.44M
134.44M – 134.44M
+16.4% YoY
|
151.97M
151.97M – 151.97M
+13.0% YoY
|
163.11M
163.11M – 163.11M
+7.3% YoY
|
| Net Income |
81.09M
est: 76.95M (+5.4%)
|
111.95M
est: 109.35M (+2.4%)
|
129.60M
129.60M – 129.60M
+18.5% YoY
|
141.75M
141.75M – 141.75M
+9.4% YoY
|
149.85M
149.85M – 149.85M
+5.7% YoY
|
| SGA |
109.04M
est: 92.77M (+17.5%)
|
105.34M
est: 111.24M (-5.3%)
|
129.51M
129.51M – 129.51M
+16.4% YoY
|
146.40M
146.40M – 146.40M
+13.0% YoY
|
157.12M
157.12M – 157.12M
+7.3% YoY
|
| EPS |
0.20
est: 0.19 (+5.3%)
|
0.28
est: 0.27 (+3.7%)
|
0.32
0.32 – 0.32
+18.5% YoY
|
0.35
0.35 – 0.35
+9.4% YoY
|
0.37
0.37 – 0.37
+5.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Achitdej Archapairoj | Chief Accounting Officer | — | male |
| Krisada Kittigowittana | Chief Research and Development Officer & Executive Director | — | — |
| Panvipa Krisdaphong | Executive Vice Chairman of the Board of Directors | — | — |
| Suttisak Jedsadapaisid | Chief Operating Officer & Executive Director | — | male |
| Thanuwatt Jaimsuwan | Chief Financial Officer | — | male |
| Theeraya Krisdaphong | Chief Executive Officer & Executive Director | — | — |
| Wanwisa Thongart | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SNPS.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
